These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12119798)

  • 1. The heart, kidney, and brain as target organs in hypertension.
    Mensah GA; Croft JB; Giles WH
    Cardiol Clin; 2002 May; 20(2):225-47. PubMed ID: 12119798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent insights in the development of organ damage caused by hypertension.
    Persu A; De Plaen JF
    Acta Cardiol; 2004 Aug; 59(4):369-81. PubMed ID: 15368798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of target organ damage caused by hypertension: therapeutic potential.
    Cohuet G; Struijker-Boudier H
    Pharmacol Ther; 2006 Jul; 111(1):81-98. PubMed ID: 16288809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure biofeedback treatment, organ damage and sympathetic activity in mild hypertension.
    Nakao M; Nomura S; Shimosawa T; Fujita T; Kuboki T
    Psychother Psychosom; 1999; 68(6):341-7. PubMed ID: 10559715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?
    Piskorz D
    High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):9-17. PubMed ID: 31975151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target organ damage and associated clinical conditions among Nigerians with treated hypertension.
    Ayodele OE; Alebiosu CO; Salako BL; Awoden OG; Abigun AD
    Cardiovasc J S Afr; 2005; 16(2):89-93. PubMed ID: 15915275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proven and new parameters of hypertensive target organ damage].
    Schmidt BM; Schmieder RE
    Dtsch Med Wochenschr; 2006 Nov; 131(46 Spec No):H20-3. PubMed ID: 17109244
    [No Abstract]   [Full Text] [Related]  

  • 9. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.
    Mulè G; Castiglia A; Cusumano C; Scaduto E; Geraci G; Altieri D; Di Natale E; Cacciatore O; Cerasola G; Cottone S
    Adv Exp Med Biol; 2017; 956():279-306. PubMed ID: 27873229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
    Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between ambulatory arterial stiffness index and subclinical target organ damage in hypertensive patients.
    García-García A; Gómez-Marcos MA; Recio-Rodriguez JI; González-Elena LJ; Parra-Sanchez J; Fe Muñoz-Moreno M; Alonso CP; Gude F; García-Ortiz L
    Hypertens Res; 2011 Feb; 34(2):180-6. PubMed ID: 20962781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and prevention of target organ damage.
    Padmavati S
    J Hum Hypertens; 1996 Feb; 10 Suppl 1():S85-7. PubMed ID: 8965298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension strategies for therapeutic intervention and prevention of end-organ damage.
    Houston MC
    Prim Care; 1991 Sep; 18(3):713-53. PubMed ID: 1946795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classic papers symposium: ambulatory blood pressure monitoring and hypertensive target organ damage.
    DiPette DJ; Townsend RR
    Am J Med Sci; 1996 Nov; 312(5):221-4. PubMed ID: 8900385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation.
    Dawood T; Schlaich MP
    Minerva Cardioangiol; 2009 Dec; 57(6):687-704. PubMed ID: 19942842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and cardiac complications of hypertension.
    Blumenfeld JD
    Clin Symp; 1994; 46(4):3-32. PubMed ID: 7874866
    [No Abstract]   [Full Text] [Related]  

  • 19. The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients.
    Trimarco B; Santoro C; Pepe M; Galderisi M
    Intern Emerg Med; 2017 Dec; 12(8):1093-1099. PubMed ID: 28770426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of hypertensive renal damage: implications for therapy.
    Bidani AK; Griffin KA
    Hypertension; 2004 Nov; 44(5):595-601. PubMed ID: 15452024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.